沙格列汀联合胰岛素治疗老年2型糖尿病的临床效果及对血脂的影响

Clinical Efficacy of Saxagliptin combined with Insulin in the Treatment of Elderly Type 2 Diabetes Mellitus

目的探讨沙格列汀联合胰岛素治疗老年2型糖尿病,对患者血糖控制效果及对患者血脂水平的影响。方法选取2015年01月-2017年12月于某院接受治疗的老年2型糖尿病患者90例,依据随机数字表法分为观察组与对照组,每组各45例。对照组行胰岛素治疗方案,观察组行沙格列汀联合胰岛素治疗方案。比较2组患者血糖控制情况、胰岛β细胞功能变化、血脂水平变化以及不良反应发生情况。结果治疗前2组患者血糖指标、胰岛β细胞功能、血脂水平,差异无统计学意义(P>0.05)。治疗后观察组患者血糖指标(FBG7.21±2.69mmol/L,2hPG8.83±1.10mmol/L,HbA1c7.10±0.89%)、胰岛β细胞功能(FCP2.41±0.30ng/ml,2h CP4.23±0.32ng/ml,HOMA-IR9.10±3.02,HOMA-B172.62±45.52)、血脂水平(TG2.63±0.80mmol/l,TC4.99±1.01mmol/l,LDL2.92±0.38mmol/l,HDL1.29±0.20mmol/l)改善更为显著,与对照组相比差异有统计学意义(P<0.05)。2组患者不良反应发生率分别为17.78%和13.33%,组间差异无统计学意义(P>0.05)。结论老年2型糖尿病患者行沙格列汀联合胰岛素治疗,能够有效改善患者血糖、胰岛β细胞功能以及血脂水平,药物安全性高,具有进一步探讨的临床意义。

Objectives To explore clinical efficacy of saxagliptin combined with Insulin in the treatment of elderly type 2 diabetes mellitus. Methods Ninety elderly patients with type 2 diabetes mellitus were selected and divided into observation group and control group according to random number table method. Each group had 45 patients(from January 2015 to December 2017). The control group received insulin treatment, and the observation group received the treatment of sgletine combined with insulin. Blood glucose control, islet beta cell function,serum lipid levels and adverse reactions were compared between the two groups. Results There was no significant difference in blood glucose, islet beta cell function and serum lipid levels between the two groups before treatment(P<0.05). The incidence of adverse reactions was 17.78% and 13.33% respectively. There was no significant difference between the two groups(P>0.05). Conclusions Sagliptin combined with insulin therapy could effectively improve blood glucose, islet beta cell function and blood lipid levels in elderly patients with type 2 diabetes mellitus. It had high drug safety and clinical significance for further study.